Disease Info Card

Amyotrophic Lateral Sclerosis

Information about Amyotrophic Lateral Sclerosis: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Amyotrophic Lateral Sclerosis

Most recent studies have shown that Amyotrophic Lateral Sclerosis shares some biological mechanisms with abnormal-degeneration, alzheimers-disease, atrophy, cerebrovascular-accident, dementia, frontotemporal-lobar-degeneration, huntington-disease, motor-neuron-disease, multiple-sclerosis, muscular-atrophy, nerve-degeneration, nervous-system-disorder, nervousness, neurodegenerative-disorders, neuromuscular-diseases, parkinson-disease, primary-lateral-sclerosis, sclerosis, spinal-muscular-atrophy, weakness.

Among the many pathways, these few ones have gauged particular interests from scientists studying Amyotrophic Lateral Sclerosis, and have been seen in publications frequently: Aging, Autophagy, Cell Death, Cell Proliferation, Cognition, Immune Response, Innervation, Localization, Muscle Atrophy, Neurogenesis, Neuron Death, Neuroprotection, Pathogenesis, Programmed Cell Death, Reflex, Regeneration, Rna Processing, Secretion, Translation, Transport

Quite a number of genes have been found to play important roles in Amyotrophic Lateral Sclerosis, such as ALS2, BDNF, CASP3, CHAT, CNTF, CSF2, FUS, GDNF, GFAP, IGF1, IGFALS, LAMC2, MAPT, SLC1A2, SOD1, TARDBP, TNF, TRH, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.